After $16.7bn Mead Johnson bid, is Reckitt Benckiser Group plc a buy?

Should you pile into Reckitt Benckiser Group Plc (LON:RB) as it looks to buy US baby food giant Mead Johnson Nutrition CO (NYSE:MJN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares of Reckitt Benckiser (LSE: RB) shot to the top of the leader board this morning after it confirmed it was in talks to acquire US baby foods group Mead Johnson Nutrition, whose brands include Enfamil infant formula.

Is Mead Johnson a good buy for Reckitt? Will the deal happen? And should you snap up shares of the FTSE 100 consumer goods powerhouse?

A good buy?

Reckitt is looking to buy Mead Johnson for $90 a share in cash, valuing the US firm at $16.7bn. This is affordable for Reckitt, whose market cap is £50bn at a current share price of 7,100p (up 4% on the day). It expects to finance the deal with a combination of cash and debt “whilst retaining a strong investment grade credit rating”.

As well as being affordable, the valuation looks attractive. The proposed $90 a share represents 17 times Mead Johnson’s forecast 2017 earnings before interest, tax, depreciation and amortisation (EBITDA), which compares favourably with the 20 times forecast EBITDA Danone is paying for WhiteWave Foods.

Mead Johnson could also be a good buy for Reckitt because it further diversifies its range of consumer categories, which are currently best represented by Lysol cleaning, Durex condoms, Nurofen painkillers and Scholl footcare. Mead Johnson’s strength in Asia, particularly China, would also usefully increase Reckitt’s exposure to higher-growth emerging markets.

Will the deal happen?

Reckitt’s announcement contained the usual disclaimer that there’s “no certainty that any transaction will ultimately be agreed, nor as to the terms on which any transaction might occur”. However, there looks to be a good chance of it going ahead for a number of reasons.

Reckitt said today that it’s in “advanced negotiations” and at the stage of “due diligence and contract discussion”. Another positive for a go-ahead is that the acquisition would present no antitrust obstacles to Reckitt, something that can’t be said of Nestlé, which has been seen as a potential bidder for Mead Johnson. Meanwhile Danone, another touted bidder, is busy completing its WhiteWave Foods deal.

Should you snap up the shares?

After the rise in its shares today, Reckitt is trading on 21 times forecast 2017 earnings. That may look a bit pricey but there are a number of reasons why I believe the stock is still worth buying.

  • I reckon there’s a good chance the deal will go ahead and if so, it will be earnings-enhancing.
  • While this would be Reckitt’s biggest deal to date, it’s previously done a fine job of integrating some other pretty sizeable companies.
  • There are always analysts who question the advisability of an acquisition but the market’s initial reaction to the news — favourable in Reckitt’s case — is often a better guide to the longer-term direction the shares will take if the deal does complete.
  • If the deal were to collapse and the share price fall back, I don’t think it would be too long before Reckitt sought out another prize asset for an earnings-enhancing acquisition. Pfizer‘s consumer-health unit, for example.

For these four reasons, I wouldn’t be put off buying Reckitt’s shares today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »